Protalix BioTherapeutics (PLX) Cash from Discontinued Operations (2015 - 2017)

Protalix BioTherapeutics' Cash from Discontinued Operations history runs 3 years deep, the most recent figure standing at 2000.0 for Q3 2017.

• In Q3 2017, Cash from Discontinued Operations rose 100.68% year-over-year to 2000.0; the TTM figure through Sep 2017 stood at 116000.0 (down 97.19% YoY), while the FY2016 annual figure was 11000.0, down 100.74% from the prior year.
• Cash from Discontinued Operations was 2000.0 for Q3 2017 at Protalix BioTherapeutics, up from 8000.0 in the prior quarter.
• In the past five years, Cash from Discontinued Operations ranged from a high of 4138000.0 in Q4 2015 to a low of 1406000.0 in Q3 2015.
• Historically, Cash from Discontinued Operations has averaged 159100.0 across 3 years, with a median of 131000.0 in 2015.
• The sharpest annual moves came in 2016 and 2017: Cash from Discontinued Operations surged 164.72% in 2016, then plunged 101.25% in 2017.
• A 3-year view of Cash from Discontinued Operations shows it stood at 4138000.0 in 2015, then plunged by 107.15% to 296000.0 in 2016, then soared by 100.68% to 2000.0 in 2017.
• The last three Cash from Discontinued Operations figures came in at 2000.0 (Q3 2017), 8000.0 (Q2 2017), and 122000.0 (Q1 2017), per Business Quant data.